ibandronic acid has been researched along with Brittle Bone Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayer, M; Kutílek, Š; Ondrušová, E; Plášilová, I; Skálová, S | 1 |
| Han, LW; Hu, YY; Jiang, Y; Li, M; Liu, HJ; Meng, XW; Wang, O; Xia, WB; Xing, XP; Xu, L; Yu, W | 1 |
1 trial(s) available for ibandronic acid and Brittle Bone Disease
| Article | Year |
|---|---|
Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta.
Topics: Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Ibandronic Acid; Infant; Infant, Newborn; Infusions, Intravenous; Male; Osteogenesis Imperfecta; Prospective Studies | 2011 |
1 other study(ies) available for ibandronic acid and Brittle Bone Disease
| Article | Year |
|---|---|
Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta.
Topics: Administration, Oral; Adolescent; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Osteogenesis Imperfecta | 2021 |